Liezhi Wang
Overview
Explore the profile of Liezhi Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
41
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu C, Jiang H, Wang L, Jiang Z, Jin C
Front Oncol
. 2025 Feb;
15:1404695.
PMID: 39926278
Objective: We carried out the meta-analysis to determine the predictive value of baseline neutrophil to lymphocyte ratio (NLR) and derived neutrophil to lymphocyte ratio (dNLR) levels in patients with gastroesophageal...
2.
Ma J, Mo J, Feng Y, Wang L, Jiang H, Li J, et al.
Front Pharmacol
. 2024 Sep;
15:1450847.
PMID: 39234106
Introduction: Luteolin, a natural compound commonly used in traditional Chinese medicine, shows clinical potential as an anti-liver cancer agent. The mechanisms underlying the anti-liver cancer effect of luteolin are limited...
3.
Jiang H, Liao J, Wang L, Jin C, Mo J, Xiang S
Front Immunol
. 2023 Jun;
14:1163967.
PMID: 37325670
Advanced hepatocellular carcinoma (HCC) is a formidable public health problem with limited curable treatment options. Axitinib, an oral tyrosine kinase inhibitor, is a potent and selective second-generation inhibitor of vascular...
4.
Lin W, Wang K, Mo J, Wang L, Song Z, Jiang H, et al.
Cancer Med
. 2023 May;
12(13):14413-14425.
PMID: 37212524
Background: Liver cancer is a highly malignant disease and the third leading cause of cancer death worldwide. Abnormal activation of PI3K/Akt signaling is common in cancer, but whether phosphoinositide-3-kinase regulatory...
5.
Mo J, Tong Y, Ma J, Wang K, Feng Y, Wang L, et al.
Front Pharmacol
. 2023 Feb;
14:1049953.
PMID: 36817123
(Batal.) Iljinsk., a subtropical tree belonging to the family Juglandaceae, is rich in polysaccharides, flavonoids, and terpenoids. It has important pharmacological effects such as lowering blood lipids, blood sugar, and...
6.
Xiao C, Liu S, Ge G, Jiang H, Wang L, Chen Q, et al.
Front Pharmacol
. 2023 Feb;
14:1086813.
PMID: 36814489
Hepatocellular carcinoma (HCC) is one of the most common digestive malignancies. HCC It ranges as the fifth most common cause of cancer mortality worldwide. While The prognosis of metastatic or...
7.
Kong F, Wang K, Wang L
Discov Oncol
. 2022 Nov;
13(1):131.
PMID: 36434140
Background: Hepatocellular carcinoma (HCC) is a malignant tumor with poor prognosis. N6-methyladenosine (m6A) modification has dual biological functions in RNA modification and plays an important role in HCC. Methods: The...
8.
Zhao S, Wu W, Jiang H, Ma L, Pan C, Jin C, et al.
Front Immunol
. 2021 Nov;
12:731527.
PMID: 34804015
Advanced hepatocellular carcinoma (HCC) remains a formidable health challenge worldwide, with a 5-year survival rate of 2.4% in patients with distant metastases. The hepatocyte growth factor/cellular-mesenchymal-epithelial transition (HGF/c-Met) signaling pathway...